Primary systemic amyloidosis (AL amyloidosis) is a rare monoclonal plasma cell proliferative disorder. The disease is insidious, progressive, and uniformly fatal with a median survival of approximately 12-18 months. The AL amyloid protein fibrils deposit throughout the body and produce the characteristic clinical manifestations and syndromes. Response rates with standard alkylator therapy are only 20-30 percent. Peripheral stem cell transplantation may yield responses in 29-55 percent of patients, but concerns exist about selection bias confounding these data. The pathogenesis and treatment of primary systemic amyloidosis can be approached from several perspectives: the plasma cell clone and the bone marrow microenvironment; the clonal immunoglobulin fragment, which is the amyloid precursor; and the microenvironment of the target tissue, which supports amyloid deposition and possibly formation. This proposal is a therapeutic trial exploiting the favorable results seen with thalidomide in patients with multiple myeloma. The laboratory correlates are designed to study baseline characteristics and response characteristics at the level of the plasma cell clone and its microenvironment as well as of the amyloidogenic immunoglobulin and the amyloid fibril. For these studies, the clinical expertise of several Mayo Clinic investigators and of Dr Alan Solomon's group at the University of Tennessee will be utilized. This study will provide the opportunity to prospectively study information on bone marrow microvessels, vascular derived endothelial growth factor (VEGF) expression, apoptosis and proliferation of plasma cells, and amyloid fibril characteristics, both before and after therapy with thalidomide. Though primary systemic amyloidosis is a rare disorder, information about the plasma cell clone and immunoglobulin will be helpful not only to patients with AL amyloidosis but will also be useful in understanding two much less rare disorders, i.e. multiple myeloma and monoclonal gammopathy of undetermined significance. If thalidomide demonstrates activity in patients with primary systemic amyloidosis, we will use it as a component of a future multidrug Phase II trial, and the pertinent scientific correlates will be expanded upon based on positive findings. This """"""""Quick Trials"""""""" (PA-00-047) application is designed to provide an essential research component to the clinical trial that will result in new knowledge on the pathogenesis of AL amyloidosis. The ultimate goal of the proposed studies is to improve the prognosis of patient with this fatal disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA091561-02
Application #
6515122
Study Section
Special Emphasis Panel (ZRG1-CONC (01))
Program Officer
Wu, Roy S
Project Start
2001-04-10
Project End
2004-03-31
Budget Start
2002-04-01
Budget End
2004-03-31
Support Year
2
Fiscal Year
2002
Total Cost
$226,238
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Dispenzieri, A; Gertz, M A; Kumar, S K et al. (2014) High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart 100:383-8
Warsame, Rahma; Gertz, Morie A; Lacy, Martha Q et al. (2012) Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol 87:647-51
Dispenzieri, Angela; Katzmann, Jerry A; Kyle, Robert A et al. (2012) Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 87:517-23
Dispenzieri, Angela; Armitage, James O; Loe, Matt J et al. (2012) The clinical spectrum of Castleman's disease. Am J Hematol 87:997-1002
Dispenzieri, Angela; Dingli, David; Kumar, Shaji K et al. (2010) Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol 85:757-9
Dispenzieri, Angela; Lacy, Martha Q; Zeldenrust, Steven R et al. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109:465-70
Abraham, Roshini S; Ballman, Karla V; Dispenzieri, Angela et al. (2005) Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 105:794-803
Dispenzieri, Angela; Gertz, Morie A; Kyle, Robert A et al. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-7
Dispenzieri, Angela; Kyle, Robert A; Lacy, Martha Q et al. (2004) Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 103:3960-3
Dispenzieri, Angela; Gertz, Morie A; Kyle, Robert A et al. (2004) Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104:1881-7

Showing the most recent 10 out of 13 publications